We have established a new subsidiary company and office in Amsterdam – our first in continental Europe – and appointed Ludmila Curi as an EU QPPV (Qualified Person responsible for Pharmacovigilance).
Ludmila is based in Amsterdam and, as a qualified medical doctor, she will also provide support to our existing pharmacovigilance safety physician. She is delighted to join Panacea and is looking forward to exploring the many opportunities that are created by being located in the city, which is a growing hub for pharma companies.
Our Chairman, Stuart Colligon, welcomed her to the team and commented: “Opening our first office in continental Europe is a significant milestone for us. The fact that we have recruited a QPPV with Ludmila’s expertise and experience – and that she has relocated from Argentina to The Netherlands to work with us – illustrates Panacea’s growing international reputation within the industry.”
Ludmila is now providing clients that are MAHs (Marketing Authorisation Holders) with pharmacovigilance and medical expertise. As an EU QPPV, she strengthens our existing team of QPPVs (based in the UK and Republic of Ireland) who are responsible for providing outsourced QPPV services to MAHs both within the EU and in the UK.
A subsidiary – Panacea B.V. – has been set up to support the company’s expansion in continental Europe. Amsterdam was chosen because it already has a thriving pharma sector, and a growing pool of talented professionals who live and work in and around the city. Other key advantages are the excellent transport links (Panacea’s office is in the World Trade Center Schiphol Airport complex), and the fact that the European Medicines Agency (EMA) has its HQ in the city, having relocated from London in 2019 due to Brexit.